Chromatin activity of I?Ba mediates the exit from naive pluripotency
Por:
Palma, LG, Alvarez-Villanueva, D, Maqueda, M, Barrero, M, Iglesias, A, Bertran, J, Alvarez, D, Garcia-Prieto, CA, Ballare, C, Rodriguez-Cortez, V, Bueno, C, Vidal, A, Villanueva, A, Menendez, P, Stik, G, Di Croce, L, Payer, B, Esteller, M, Espinosa, L and Bigas, A
Publicada:
22 oct 2025
Ahead of Print:
22 oct 2025
Resumen:
Maintenance of pluripotency is a multifactorial process in which NF-kappa B is a negative regulator. Our previous work identified a chromatin role for I kappa B alpha, the master regulator of NF-kappa B signaling, that is critical for the proper regulation of various tissue stem cells. Here, we found that I kappa B alpha accumulates specifically in the chromatin fraction of mouse pluripotent stem cells. I kappa B alpha depletion does not affect NF-kB-dependent transcription, but causes a profound epigenetic rewiring in pluripotent stem cells, including alterations in H3K27me3, a histone mark catalyzed by Polycomb repression complex 2. Chromatin changes induced by I kappa B alpha depletion affect a subset of pluripotency genes and are associated with altered gene transcription. At the cellular level, I kappa B alpha-deficient embryonic stem cells are arrested in a naive pluripotency state when cultured in serum/LIF conditions and fail to exit pluripotency under differentiation conditions. By constructing separation-of-function mutants, we show that the effects of I kappa B alpha in regulating stem cell pluripotency are NF-kappa B-independent, but mainly rely on its chromatin-related function. Taken together, our results reveal a novel mechanism by which I kappa B alpha participates in the regulation of the pluripotent state of mouse embryonic stem cells and shed light on the interplay between inflammatory signals and the regulation of pluripotency.
Filiaciones:
Palma, LG:
Hosp Del Mar Res Inst, Program Canc Res, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Alvarez-Villanueva, D:
Hosp Del Mar Res Inst, Program Canc Res, Barcelona, Spain
Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain
Maqueda, M:
Hosp Del Mar Res Inst, Program Canc Res, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Barrero, M:
Barcelona Inst Sci & Technol, Ctr Genom Regulationlat CRG, Barcelona, Spain
Iglesias, A:
Hosp Del Mar Res Inst, Program Canc Res, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Bertran, J:
Univ Vic, Univ Cent Catalunya, Vic, Spain
Alvarez, D:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Garcia-Prieto, CA:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Ballare, C:
Barcelona Inst Sci & Technol, Ctr Genom Regulationlat CRG, Barcelona, Spain
Rodriguez-Cortez, V:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Vidal, A:
Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain
Villanueva, A:
Catalan Inst Oncol ICO IDIBELL, Barcelona, Spain
:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Carlos III Hlth Inst ISCIII, Spanish Network Adv Therapies RICORS TERAV, Madrid, Spain
Univ Barcelona, Dept Biomed, Barcelona, Spain
Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain
:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Di Croce, L:
Barcelona Inst Sci & Technol, Ctr Genom Regulationlat CRG, Barcelona, Spain
Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain
Univ Pompeu Fabra, Barcelona, Spain
Payer, B:
Barcelona Inst Sci & Technol, Ctr Genom Regulationlat CRG, Barcelona, Spain
Univ Pompeu Fabra, Barcelona, Spain
:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain
Univ Barcelona UB, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Spain
Espinosa, L:
Hosp Del Mar Res Inst, Program Canc Res, Barcelona, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Bigas, A:
Hosp Del Mar Res Inst, Program Canc Res, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Green Submitted, gold
|